8-KLeadership Changes

CVS HEALTH Corp 8-K Report, Executive Changes (Mar 6, 2015)

Filed March 6, 2015For Securities:CVS

Summary

CVS Health Corporation announced a key addition to its Board of Directors, effective March 5, 2015. Alecia A. DeCoudreaux has been elected as a new independent director. Ms. DeCoudreaux brings a wealth of experience, notably from her extensive career at Eli Lilly and Company, where she held significant legal and leadership positions, including Vice President and General Counsel. Her background also includes leadership in academia as President of Mills College and service on various educational and non-profit boards. This appointment is significant as it bolsters the Board's expertise, particularly in areas relevant to the pharmaceutical and healthcare industries. Her determination as an "independent" director aligns with corporate governance best practices and strengthens the oversight capabilities of the Board. Investors can view this as a positive step towards maintaining robust corporate governance and leveraging diverse leadership to guide the company's strategic direction.

Key Highlights

  • 1CVS Health Corporation has elected Alecia A. DeCoudreaux to its Board of Directors, effective March 5, 2015.
  • 2Ms. DeCoudreaux is considered an "independent" director under NYSE and company guidelines.
  • 3She brings extensive executive experience from Eli Lilly and Company, including roles as Vice President and General Counsel.
  • 4Ms. DeCoudreaux also served as President of Mills College, adding academic leadership experience.
  • 5Her background includes 30 years with Eli Lilly, holding various senior legal and governmental relations positions.
  • 6Her compensation as a director will be standard for non-employee directors, prorated for her service commencement.
  • 7The appointment is detailed under Item 5.02 of the 8-K filing.

Frequently Asked Questions

Alecia A. DeCoudreaux has been elected as a new, independent member of the Board of Directors at CVS Health Corporation, effective March 5, 2015. She will serve as a non-employee director.

Ms. DeCoudreaux has a strong background in the pharmaceutical industry, having spent 30 years at Eli Lilly and Company in various leadership roles, including Vice President and General Counsel. She also has experience in academic leadership as President of Mills College.

Yes, the Board of Directors has determined that Ms. DeCoudreaux meets the independence requirements set forth by the New York Stock Exchange Corporate Governance Rules and the Corporation's own Corporate Governance Guidelines.

Her compensation will be consistent with that of other non-employee directors, subject to proration based on her commencement date of service on March 5, 2015.